Company news

Vaxcyte, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Vaxcyte Announces Pricing of $100 Million Public Offering

January 12, 2022

Vaxcyte Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

January 11, 2022

Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease

January 5, 2022

Vaxcyte Reports Third Quarter 2021 Financial Results and Provides Business Update

November 9, 2021

Vaxcyte Appoints Carlos Paya and Michael Kamarck to Its Board of Directors

October 27, 2021

Canbud Appoints New Board Member and Provides Acquisition Update

October 7, 2021

Vaxcyte to Present at Guggenheim 2nd Annual Vaccine and Infectious Disease Conference

September 27, 2021

Vaxcyte to Present at 2021 Cantor Virtual Global Healthcare Conference

September 20, 2021

Vaxcyte Appoints Annie Drapeau and Teri Loxam to Its Board of Directors

September 19, 2021

Vaxcyte Reports Second Quarter 2021 Financial Results and Provides Business Update

August 10, 2021

Vaxcyte Announces Expanded CARB-X Award to Advance Development of VAX-A1, a Vaccine to Prevent Group A Streptococcus Infections

August 4, 2021

Vaxcyte to Present at the Jefferies Virtual Healthcare Conference

May 26, 2021

Vaxcyte Reports First Quarter 2021 Financial Results and Provides Business Update

May 10, 2021

Vaxcyte Announces Publication of Preclinical Data Supporting the Potential of VAX-24 for the Prevention of Invasive Pneumococcal Disease

May 9, 2021

Vaxcyte to Present at BofA Securities 2021 Health Care Conference

May 5, 2021

Vaxcyte to Present at 20th Annual Needham Virtual Healthcare Conference

April 4, 2021

Vaxcyte Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

March 28, 2021

Vaxcyte to Report Fourth Quarter and Full Year 2020 Financial Results on March 29, 2021

March 21, 2021

Vaxcyte Announces Publication of Preclinical Proof-of-Concept Data Supporting Potential of VAX-A1, a Novel Conjugate Vaccine Designed to Prevent Group A Strep Infections

January 5, 2021

Vaxcyte Promotes Andrew Guggenhime to President and Chief Financial Officer

December 21, 2020

Vaxcyte to Present at Evercore ISI 3rd Annual HealthCONx Conference

November 23, 2020

Vaxcyte Reports Third Quarter 2020 Financial Results and Provides Business Update

November 11, 2020

Vaxcyte to Present at Jefferies Virtual London Healthcare Conference

November 9, 2020

Vaxcyte to Present at 2020 Cantor Virtual Global Healthcare Conference

September 8, 2020

Vaxcyte Reports Second Quarter 2020 Financial Results and Provides Business Update

August 11, 2020

Vaxcyte Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

June 15, 2020

← Newer news releases

Calls

Decks

The 5 newest of 9 decks. Every deck is listed under its year.